Amicus Therapeutics Inc. (FOLD)’s Financial Results Comparing With Synthorx Inc. (NASDAQ:THOR)

We will be comparing the differences between Amicus Therapeutics Inc. (NASDAQ:FOLD) and Synthorx Inc. (NASDAQ:THOR) as far as dividends, analyst recommendations, profitability, risk, earnings and valuation, institutional ownership are concerned. The two businesses are rivals in the Biotechnology industry.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Amicus Therapeutics Inc. 108.59M 26.37 419.38M -2.15 0.00
Synthorx Inc. N/A 0.00 65.27M -1.75 0.00

Demonstrates Amicus Therapeutics Inc. and Synthorx Inc. earnings per share (EPS), top-line revenue and valuation.

Profitability

Table 2 shows us Amicus Therapeutics Inc. and Synthorx Inc.’s return on assets, net margins and return on equity.

Net Margins Return on Equity Return on Assets
Amicus Therapeutics Inc. -386.20% -94.9% -52.1%
Synthorx Inc. 0.00% 0% 0%

Liquidity

The Current Ratio of Amicus Therapeutics Inc. is 7.3 while its Quick Ratio stands at 7.2. The Current Ratio of rival Synthorx Inc. is 27 and its Quick Ratio is has 27. Synthorx Inc. is better equipped to clear short and long-term obligations than Amicus Therapeutics Inc.

Analyst Ratings

The Ratings and Recommendations for Amicus Therapeutics Inc. and Synthorx Inc. are featured in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Amicus Therapeutics Inc. 0 0 3 3.00
Synthorx Inc. 0 0 1 3.00

Amicus Therapeutics Inc. has a 67.40% upside potential and an average target price of $19. Competitively the average target price of Synthorx Inc. is $30, which is potential 134.38% upside. The information presented earlier suggests that Synthorx Inc. looks more robust than Amicus Therapeutics Inc. as far as analyst view.

Insider and Institutional Ownership

Institutional investors held 0% of Amicus Therapeutics Inc. shares and 86.1% of Synthorx Inc. shares. About 0.9% of Amicus Therapeutics Inc.’s share are held by insiders. Insiders Competitively, held 17% of Synthorx Inc. shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Amicus Therapeutics Inc. -4.35% -7.39% 12.06% 18.41% -11.94% 30.9%
Synthorx Inc. -5.84% -11.71% -1.29% 0% 0% -7.19%

For the past year Amicus Therapeutics Inc. has 30.9% stronger performance while Synthorx Inc. has -7.19% weaker performance.

Summary

On 7 of the 10 factors Synthorx Inc. beats Amicus Therapeutics Inc.

Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. Its principal product is the migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease, which has completed two global Phase III registration studies. The company is also developing SD-101, which is in Phase III clinical study for the treatment of the genetic connective tissue disorder epidermolysis bullosa; and AT3375 to treat Parkinson's disease. It is conducting a Phase 1/2 clinical study of ATB200-02 to investigate pompe treatment paradigm in pompe patients. The company has strategic alliance with GlaxoSmithKline plc to develop and commercialize migalastat as a monotherapy and in combination with ERT for Fabry disease. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.